Wakayama Train Company Releases Calendar of Tama and Other Feline Stationmasters
Nitama sits beside the 2024 cat calendar produced by Wakayama Electric Railway Co. in Kinokawa, Wakayama Prefecture.
15:16 JST, September 28, 2023
WAKAYAMA — Wakayama Electric Railway Co. released on Wednesday a desktop calendar for 2024 that contains adorable photos of five cats, including Tama, the first feline stationmaster of Kishi Station in Kinokawa, Wakayama Prefecture, which is on the company’s Kishigawa Line.
The two current cat stationmasters of the line were at Kishi Station on Wednesday to help launch and promote the calendar. The cats are Yontama, stationmaster of Idakiso Station in Wakayama, and Tama II or Nitama, who is the second cat stationmaster of Kishi Station.
“It is designed to take a load off one’s mind. I think it brightens up the home, so I hope everyone will put it on display,” said Mitsunobu Kojima, the president of the railway company.
The calendar contains the photos of five cats including past and current stationmasters, and comments supposedly made by each cat. The pages can be cut out and used as postcards.
The calendar is available at Kishi and Idakiso stations as well as on the company’s online store (https://shop.wakayama-dentetsu.co.jp/).
Top Articles in Features
-
Tokyo’s New Record-Breaking Fountain Named ‘Tokyo Aqua Symphony’
-
High-Hydration Bread on the Rise, Seeing Increase in Specialty Shops, Recipe Searches
-
Japanese Students Use Traditional Pickle to Create Novel Wagashi Confectionery
-
Heirs to Kyoto Talent: Craftsman Works to Keep Tradition of ‘Kinran’ Brocade Alive Through Initiatives, New Creations
-
My Spendthrift Mother Constantly Asks Me for Money
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Videos Plagiarized, Reposted with False Subtitles Claiming ‘Ryukyu Belongs to China’; Anti-China False Information Also Posted in Japan
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

